Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02787551 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 514
- Enrollment target
NCT02787551 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 514 participants.
The verdict
NCT02787551, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 514 participants
- Enrollment target
Study Summary
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change. Secondary Objectives: To compare the overall efficacy and safety of the insulin glargine/lixisenatide FRC to GLP-1 RA on top of metformin (with or without pioglitazone, with or without sodium-glucose co-transporter 2 \[SGLT2\] inhibitor) in participants with type 2 diabetes. To evaluate safety, efficacy and other endpoints of FRC up to the end of the extension period.
Interventions
- DRUG liraglutide
- DRUG exenatide
- DRUG Insulin glargine/lixisenatide fixed ratio combination
- DRUG exenatide extended-release
- DRUG albiglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2016-07-06 |
| Est. Completion | 2018-11-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02787551
The ClinicalTrials.gov registry entry for NCT02787551 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 514 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which liraglutide is the first listed.
NCT02787551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02787551 about?
NCT02787551 is a clinical study titled "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period". Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change. Secondary Objectives: To compare the overall efficacy and safety of the insulin glargine/lixisenatide FRC...
What is the current status of trial NCT02787551?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 514 participants. The study started on 2016-07-06. Estimated completion is 2018-11-17.
What interventions are being tested in trial NCT02787551?
The interventions under investigation include: liraglutide (DRUG), exenatide (DRUG), Insulin glargine/lixisenatide fixed ratio combination (DRUG), exenatide extended-release (DRUG), albiglutide (DRUG).
Who is sponsoring clinical trial NCT02787551?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.